FindMyKOL
Clinical trialNCT03585348CompletedObservational

Provider Variability in the Use of Neuromuscular Blocking Drugs and Reversal

NCT03585348 is an observational study sponsored by Beth Israel Deaconess Medical Center. As of 18 Nov 2026, it is completed. It studies Neuromuscular Blockade, Residual Curarisation, Postoperative and 1 more condition. The registry lists an enrollment of 265,537 participants at 2 sites in 1 country. The registry lists a start date of 29 Jun 2018 and a primary completion date of 31 Mar 2021.

SponsorBeth Israel Deaconess Medical Center →Enrollment265,537Neuromuscular BlockadeResidual Curarisation, PostoperativeSurgery Under General Anaesthesia
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03585348
FieldValue
Registry IDNCT03585348
StatusCompleted
Study typeObservational study
Lead sponsorBeth Israel Deaconess Medical Center
Enrollment265,537
Registered sites2
Countries1
ConditionsNeuromuscular Blockade, Residual Curarisation, Postoperative and Surgery Under General Anaesthesia
Start29 Jun 2018
Primary completion31 Mar 2021
Study completion31 Mar 2021
Last update posted25 Aug 2021

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The use of neuromuscular blocking agents during surgery is associated with postoperative respiratory complications and increased risk of readmission to the hospital following ambulatory surgery. Understanding the clinical behavior of providers is essential in devising and assessing quality improvement projects since it is primarily individuals who determine the utilization of neuromuscular blocking drugs and reversal agents, not institutions. Therefore, the primary objective of this study is to determine the variability between individual anesthesia providers (attending physician, resident, nurse anesthetists) in the use of neuromuscular blocking drugs and reversal agents, using advanced statistical methods to adjust for differences in patient and procedure case mix. The investigators hypothesize that variance between individual anesthesia providers in the use of neuromuscular blocking drugs and reversal agents differs depending on provider type.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Massachusetts, United States2 sites
  • Beth Israel Deaconess Medical Center

    Boston

  • Massachusetts General Hospital

    Boston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 2 sitesMA2Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT03585348

Each answer restates registry values shown on this page.

What is NCT03585348?

NCT03585348 is an observational study sponsored by Beth Israel Deaconess Medical Center. It studies Neuromuscular Blockade, Residual Curarisation, Postoperative and 1 more condition.

Who leads NCT03585348?

The registry names Philipp Fassbender, MD (principal investigator, Beth Israel Deaconess Medical Center) as the overall official.

Where does NCT03585348 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.

When did NCT03585348 end?

The registry lists a primary completion date of 31 Mar 2021 and a study completion date of 31 Mar 2021. The sponsor last updated the record on 25 Aug 2021.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.